Bionano Genomics (BNGO) Non-Current Assets (2017 - 2026)

Bionano Genomics has disclosed Non-Current Assets across 10 years of filings, most recently posting $25.8 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $25.8 million, down 22.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $117.6 million (down 34.59% YoY), and the FY2025 annual result was $28.2 million, down 24.16% from the prior year.
• Non-Current Assets came in at $25.8 million for Q1 2026 at Bionano Genomics, down from $28.2 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $150.2 million in Q4 2022 to a low of $25.8 million in Q1 2026.
• The 5-year median for Non-Current Assets is $72.4 million (2024), against an average of $75.7 million.
• Across the five-year window, Non-Current Assets surged 624.51% in 2022 and slumped 53.77% in 2024, its largest moves.
• Bionano Genomics' Non-Current Assets stood at $150.2 million in 2022, then tumbled by 50.54% to $74.3 million in 2023, then sank by 49.95% to $37.2 million in 2024, then retreated by 24.16% to $28.2 million in 2025, then slipped by 8.4% to $25.8 million in 2026.
• The last three Non-Current Assets figures came in at $25.8 million (Q1 2026), $28.2 million (Q4 2025), and $30.3 million (Q3 2025), per Business Quant data.